首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1122334

鈣通道阻滯劑市場：按藥物類別、適應症（高血壓、胸痛、心律失常等）、按分銷渠道、按地區 - 規模、份額、前景、機會分析，2022-2030

Calcium Channel Blocker Drugs Market, by Drug Class, by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others ), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月16日 | 出版商:

Coherent Market Insights | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

鈣拮抗劑是用於治療與心絞痛相關的高血壓、心律失常和胸痛的藥物，通過阻斷一些進入心臟和動脈的鈣而有效。鈣通道阻滯劑有許多不同的類型，從短效溶解片劑到緩釋膠囊。劑量取決於患者的一般情況和病史。

此外，慢性腎病是一種腎功能在數年內逐漸下降的疾病。隨著腎功能衰竭的進展和器官功能的嚴重受損，危險水平的廢物和水會在體內迅速積聚。治療旨在阻止或減緩疾病的進展，而根本原因鈣通道阻滯劑通常用於治療慢性腎病或其根本原因。

市場動態

預計心血管疾病、肥胖和不健康生活方式的流行將在預測期內推動市場增長。

例如，根據世界衛生組織 2022 年的數據，2019 年估計有 1790 萬人死於心血管疾病，其中 85% 的死亡發生在全球心髒病發作和中風。

預計鈣通道阻滯劑的不斷推出和批准將標誌著預測期內市場的顯著增長。

例如，2022 年 6 月，製藥公司 CMP Pharma 宣布了 1mg 的長效鈣通道阻滯劑氨氯地平苯磺酸鹽口服液，用於治療 6 歲及以下患者的高血壓。/ML，其 Noricva（氨氯地平）口服溶液獲得美國食品和藥物管理局的批准。

本研究的主要特點

本報告對以 2021 年為基準年的預測期（2022-2030 年）內的全球鈣通道阻滯劑市場、市場規模（百萬美元）和復合年增長率 (CAGR%) 進行了深入分析。增加。
解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
它還提供有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
基於公司亮點、產品組合、關鍵亮點、業績和戰略等參數的全球鈣拮抗劑市場主要參與者的概況。
本研究涵蓋的主要公司包括：Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
此報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。這似乎是一回事。
全球鈣拮抗劑市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
利益相關者可以通過用於分析全球鈣通道阻滯劑市場的各種策略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場細分：按藥物類別
- 市場細分：按指示
- 市場細分：按分銷渠道
- 按地區劃分的市場細分
連貫的機會圖 (COM)

第 3 章市場動態、監管和趨勢分析

驅動程序
限制因素
商機
影響分析
主要發展戰略
併購場景
市場趨勢
品牌分析
監管場景
PEST 分析
定價分析

第 4 章全球鈣通道阻滯劑市場 - 冠狀病毒 (COVID-19) 大流行的影響

COVID-19 的流行病學特徵
對製造業的影響
對製造業的影響

第 5 章全球鈣通道阻滯劑市場，按藥物類別，2017-2030 年

苯佐西平
二氫□啶
苯烷基胺

第 6 章全球鈣通道市場：按疾病適應症，2017-2030

高血壓
胸痛
心律失常
其他（血管疾病、冠狀動脈疾病等）

第 7 章。全球鈣通道阻滯劑市場，按分銷渠道：2017-2030 年

醫院藥房
零售藥房
在線藥店

第 8 章全球鈣通道阻滯劑市場：按地區分列，2017-2030 年

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
德國
英國
法國
意大利
西班牙
俄羅斯
其他歐洲地區
亞太地區
中國
印度
日本
澳大利亞
韓國
東盟
其他亞太地區
中東
海合會
以色列
其他中東
非洲
南非
中非
北非

第 9 章競爭格局

Competitive Snapshot
- Bausch Health
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd,
- Novartis AG
- Zydus Cadila
- Pfizer Inc,

第 10 章

參考資料
調查方法

簡介目錄

Product Code: CMI5153

Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ's function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease - this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study:

This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcium channel blocker drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Detailed Segmentation:

Global Calcium Channel Blocker Drugs Market, By Drug Class:
- Benzothizepine
- Dihydropyridine
- Phenylalkylamine
Global Calcium channel blocker drugs market, By Disease Indication:
- Hypertension
- Chest Pain
- Arrhythmias
- Others (Blood vessel conditions, Coronary Artery Disease etc.)
Global Calcium Channel Blocker Drugs Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Calcium Channel Blocker Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest Of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- Bausch Health*
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd,
- Novartis AG
- Zydus Cadila
- Pfizer Inc,

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Key Development Strategies
Mergers And Acquisition Scenario
Market Trends
Brand Analysis
Regulatory Scenario
PEST Analysis
Pricing Analysis

4. Global Calcium Channel Blocker Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

COVID-19 Epidemiology
Impact on Manufacturing
Impact on Manufacturing

5. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Benzothizepine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Dihydropyridine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Phenylalkylamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Chest Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Arrhythmias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others (Blood vessel conditions, Coronary Artery Disease etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. Global Calcium Channel Blocker Drugs Market, By Region, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
North America
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
South Africa
Central Africa
North Africa